• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
10SepSeptember 10, 2023

In Vitro Evaluation of PROTAC® Androgen Receptor Degrader ARV-766 for Cytochrome P450- and Transporter-Mediated Drug-Drug Interaction

10SepSeptember 10, 2023

Drug-Drug Interaction Study of the PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Combination With the CYP3A4 Inhibitor Itraconazole in Healthy Volunteers

10SepSeptember 10, 2023

The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Healthy Volunteers

10SepSeptember 10, 2023

The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of ARV-766, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Healthy Volunteers

27AugAugust 27, 2023

Development of Potent, Orally Bioavailable, and Highly Selective LRRK2 PROTAC® Degrader Molecules as Potential Disease Modifying Therapeutics for Parkinson’s Disease

27AugAugust 27, 2023

LRRK2 PROTAC® Degrader Molecules Induce Robust Biomarker Responses in Preclinical In Vivo Pharmacology Studies Following Acute and Chronic Oral Dosing

02JunJune 2, 2023

TACTIVE-U: Phase 1b/2 Umbrella Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined with Other Anticancer Treatments in ER+ Advanced or Metastatic Breast Cancer

02JunJune 2, 2023

VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

11MayMay 11, 2023

TACTIVE-N: Open-Label, Randomized, Noncomparative Neoadjuvant Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal Women with ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Localized Breast Cancer

11MayMay 11, 2023

VERITAC Update: Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

  Prev123Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE